(Q37202615)

18 August 2017

1 reference

title

Minimal residual disease diagnostics in myeloid malignancies in the post transplant period (English)

1 reference

18 August 2017

3

T Haferlach

1 reference

18 August 2017

U Bacher

1

1 reference

18 August 2017

A R Zander

2

1 reference

18 August 2017

S Schnittger

4

1 reference

18 August 2017

B Fehse

5

1 reference

18 August 2017

N Kröger

6

1 reference

18 August 2017

language of work or name

English

0 references

publication date

30 June 2008

1 reference

Bone Marrow Transplantation

18 August 2017

1 reference

18 August 2017

42

1 reference

18 August 2017

3

1 reference

18 August 2017

145-157

1 reference

https://scigraph.springernature.com/pub.10.1038/bmt.2008.185

18 August 2017

0 references

cites work

The molecular genetics of Philadelphia chromosome-positive leukemias

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Can reduced-intensity allogeneic transplantation cure older adults with AML?

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21).

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

JAK2 mutations in myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Strategies and clinical implications of chimerism diagnostics after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Monitoring of minimal residual disease in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Managing the patient with chronic myeloid leukemia through and after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Morphology of the bone marrow after stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Diagnostic problems in follow-up bone marrow biopsies of patients treated for acute and chronic leukaemias and MDS.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Chromosome and molecular abnormalities in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Evaluation of complete disease remission in acute myeloid leukemia: a prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Diagnostic pathways in acute leukemias: a proposal for a multimodal approach

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

RUNX1 gene mutation in primary myelodysplastic syndrome--the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Clinical implications of minimal residual disease monitoring for stem cell transplantation after reduced intensity and nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Specific detection of Flt3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Determination of minimal residual disease in leukaemia patients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Leukaemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: detection in remission marrow predicts outcome

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Monitoring of minimal residual disease in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Chimerism and transplant-related diagnostics

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Interphase FISH analysis of sex-mismatched BMT utilizing dual color XY probes.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Diagnostic chimerism analysis after allogeneic stem cell transplantation: new methods and markers.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Real-time PCR for monitoring minimal residual disease and chimerism in patients after allogeneic transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

How and when should we monitor chimerism after allogeneic stem cell transplantation?

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Hemopoietic chimerism following stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Assessing quantitative chimerism longitudinally: technical considerations, clinical applications and routine feasibility

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Lineage-specific chimaerism after stem cell transplantation in children following reduced intensity conditioning: potential predictive value of NK cell chimaerism for late graft rejection.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Detection of impending graft rejection and relapse by lineage-specific chimerism analysis.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Analysis of chimerism within specific leukocyte subsets for detection of residual or recurrent leukemia in pediatric patients after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Successful immunotherapy in early relapse of acute myeloid leukemia after nonmyeloablative allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Prediction of response of patients with acute nonlymphocytic leukaemia to remission induction therapy: use of clinical measurements

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Abnormal Cytogenetics at Date of Morphologic Complete Remission Predicts Short Overall and Disease-Free Survival, and Higher Relapse Rate in Adult Acute Myeloid Leukemia: Results From Cancer and Leukemia Group B Study 8461

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Allogeneic stem cell transplantation in second rather than first complete remission in selected patients with good-risk acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Salvage of patients with acute promyelocytic leukaemia with residual disease following ABMT performed in second CR using all-trans retinoic acid

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Molecular methods used for detection of minimal residual disease following hematopoietic stem cell transplantation in myeloid disorders

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Minimal residual disease based on patient specific Flt3-ITD and -ITT mutations in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Flow cytometric analysis of aberrant antigen expression of blasts using CD45 blast gating for minimal residual disease in acute leukemia and high-risk myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Detection of minimal residual disease (MRD) after bone marrow transplantation (BMT) by multi-parameter flow cytometry (MPFC).

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Multidimensional flow cytometry of marrow can differentiate leukemic from normal lymphoblasts and myeloblasts after chemotherapy and bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Efficacy of lenalidomide in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

WT1 gene expression: useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia?

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Successful rapid discontinuation of immunosuppressive therapy at molecular relapse after allogeneic bone marrow transplantation in a pediatric patient with myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

The application of comparative genomic hybridization as an additional tool in the chromosome analysis of acute myeloid leukemia and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host dis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Eradication of JAK2 V617F mutation after allogeneic transplantation in a patient with myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD).

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2008.185

7 January 2021

Identifiers

DOI

10.1038/BMT.2008.185

1 reference

18 August 2017

1 reference